Soligenix Inc. has provided a clinical update on its research into cutaneous T-cell lymphoma, reporting that interim analysis from its phase 3 FLASH2 study shows consistent response rates and that comparative study results indicate its HyBryte therapy performs favorably against an existing treatment option. The company’s announcements highlight progress in addressing CTCL, a rare form of non-Hodgkin lymphoma that primarily affects the skin and causes persistent skin lesions, plaques and tumors according to the National Cancer Institute.
The interim update indicated that the overall blinded aggregate response rate observed in patients who have completed treatment remains consistent with prior reporting. This consistency in the phase 3 FLASH2 study data represents important validation of the therapy’s potential efficacy. In biotechnology research, particularly for diseases with limited treatment options, advancing clinical research while generating positive data represents a critical combination for development programs.
Additionally, the company reported positive results from a study evaluating HyBryte against Valchlor, an existing treatment option for cutaneous T-cell lymphoma. These comparative clinical results reinforce the company’s focus on developing innovative treatments for serious conditions. The research momentum demonstrated by these announcements comes as Soligenix continues its work on CTCL treatments, with the latest news and updates relating to SNGX available in the company’s newsroom at https://ibn.fm/SNGX.
The announcements were distributed through BioMedWire, a specialized communications platform with a focus on the latest developments in the Biotechnology, Biomedical Sciences and Life Sciences sectors. BioMedWire is one of 75+ brands within the Dynamic Brand Portfolio at IBN that delivers various communication solutions, with more information available at https://www.BioMedWire.com. The platform’s full terms of use and disclaimers applicable to all content provided by BMW are available at https://www.BioMedWire.com/Disclaimer.
For rare diseases like CTCL where treatment options remain limited, positive clinical data represents significant progress toward potentially expanding therapeutic alternatives for patients. The consistent interim results from the phase 3 study combined with favorable comparative data against existing treatments suggest HyBryte may offer a meaningful advancement in CTCL treatment approaches. As research continues, these developments highlight the ongoing efforts within biotechnology to address serious medical conditions through innovative therapeutic development.
This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Soligenix Reports Positive CTCL Treatment Data in Interim Analysis and Comparative Study.